NUVB vs RARE: stock comparison and AI forecast
Nuvation Bio Inc. (NUVB) and Ultragenyx Pharmaceutical Inc. (RARE) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
NUVB Nuvation Bio Inc.
- Market Cap
- $1.61B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
RARE Ultragenyx Pharmaceutical Inc.
- Market Cap
- $1.61B
- P/E Ratio
- –
- Size
- small-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- NUVB and RARE have similar market capitalizations ($1.61B and $1.61B).
- NUVB turns -88.2% of its revenue into net income, against -100.8% for RARE.
- Both companies share the SEC industry classification Pharmaceutical Preparations.
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | NUVB | RARE |
|---|---|---|
| Market Cap | $1.61B | $1.61B |
| P/B Ratio | 6.35x | – |
| EPS | $-0.61 | $-5.83 |
| Book Value/Share | $0.72 | – |
| Revenue/Share | $0.48 | $5.90 |
| FCF/Share | – | $-4.96 |
Profitability & Margins
| Metric | NUVB | RARE |
|---|---|---|
| ROE | -59.0% | – |
| ROA | -20.1% | -46.4% |
| ROIC | -20.9% | -57.9% |
| Gross Margin | 92.8% | – |
| Operating Margin | -81.0% | -90.9% |
| Net Margin | -88.2% | -100.8% |
| EBT Margin | -88.2% | -100.2% |
| Tax Rate | 0.0% | -0.6% |
Financial Health
| Metric | NUVB | RARE |
|---|---|---|
| Current Ratio | 8.37x | 1.73x |
| Quick Ratio | 8.14x | 1.56x |
| D/E Ratio | 1.93x | – |
| Financial Leverage | 2.93x | – |
| Interest Coverage | -6.8x | -32.5x |
| Working Capital | $640M | $255M |
Cash Flow
| Metric | NUVB | RARE |
|---|---|---|
| Operating Cash Flow | -$121M | -$485M |
| Free Cash Flow | – | -$489M |
| Capital Spending | – | -$4M |
| FCF/Sales | – | -84.2% |
| CapEx/Sales | – | 0.7% |
Operational Efficiency
| Metric | NUVB | RARE |
|---|---|---|
| Asset Turnover | 0.23x | 0.46x |
| Receivables Turnover | 6.1x | 2.9x |
| Inventory Turnover | 0.6x | – |
| Fixed Assets Turnover | 237.6x | 2.5x |
| Days Sales Outstanding | 60 days | 126 days |
| Days Inventory | 594 days | – |
| Payables Period | 361 days | – |
| Cash Conversion Cycle | 293 days | – |
Income Statement
| Metric | NUVB | RARE |
|---|---|---|
| Total Revenue | $170M | $581M |
| Operating Income | -$138M | -$528M |
| Net Income | -$150M | -$586M |
| R&D Expense | $129M | $773M |
| SG&A Expense | $159M | $351M |
| Cost of Goods Sold | $12M | – |
Dividend & Shareholder Information
| Metric | NUVB | RARE |
|---|---|---|
| Shares Outstanding | 351M | 99M |
NUVB vs RARE: stock comparison and AI forecast
Which is bigger, NUVB or RARE?
NUVB and RARE have similar market capitalizations ($1.61B and $1.61B).
Which one does Intratio's AI model rank higher, NUVB or RARE?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.